Foghorn Therapeutics Inc. — Net Income by Fiscal Year
7 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/c8f66dd6-5270-40b4-ada9-80f0e6f6cfb1/serie/net-income
| Fiscal year | Net Income | Period | Evidence |
|---|---|---|---|
| FY 2025 | $-74.3M | 2025-01-01 – 2025-12-31 | evidence 0001628280-26-016814 |
| FY 2024 | $-86.6M | 2024-01-01 – 2024-12-31 | evidence 0001628280-25-010933 |
| FY 2023 | $-98.4M | 2023-01-01 – 2023-12-31 | evidence 0001628280-24-009539 |
| FY 2022 | $-108.9M | 2022-01-01 – 2022-12-31 | evidence 0001628280-23-007297 |
| FY 2021 | $-101.3M | 2021-01-01 – 2021-12-31 | evidence 0001628280-22-005753 |
| FY 2020 | $-68.8M | 2020-01-01 – 2020-12-31 | evidence 0001193125-21-085777 |
| FY 2019 | $-51.1M | 2019-01-01 – 2019-12-31 | evidence 0001193125-21-085777 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
Foghorn Therapeutics Inc. — all facts · Revenue · Operating Income